PL372490A1 - 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej - Google Patents

5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej

Info

Publication number
PL372490A1
PL372490A1 PL03372490A PL37249003A PL372490A1 PL 372490 A1 PL372490 A1 PL 372490A1 PL 03372490 A PL03372490 A PL 03372490A PL 37249003 A PL37249003 A PL 37249003A PL 372490 A1 PL372490 A1 PL 372490A1
Authority
PL
Poland
Prior art keywords
phtalide
propionylamino
trifluoromethylphenyl
cyclopropyl
hydroxy
Prior art date
Application number
PL03372490A
Other languages
English (en)
Inventor
Norbert Schmees
Manfred Lehmann
Ulrike Fuhrmann
Peter Muhn
Christa Hegele-Hartung
Michael Klotzbücher
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005530A external-priority patent/EP1344776A1/en
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL372490A1 publication Critical patent/PL372490A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL03372490A 2002-03-11 2003-03-10 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej PL372490A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36304402P 2002-03-11 2002-03-11
EP02005530A EP1344776A1 (en) 2002-03-11 2002-03-11 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders

Publications (1)

Publication Number Publication Date
PL372490A1 true PL372490A1 (pl) 2005-07-25

Family

ID=27806515

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372490A PL372490A1 (pl) 2002-03-11 2003-03-10 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej

Country Status (26)

Country Link
US (1) US7388006B2 (pl)
EP (1) EP1482925B1 (pl)
JP (1) JP2005526064A (pl)
CN (1) CN1652768A (pl)
AR (1) AR035904A1 (pl)
AU (1) AU2003209720A1 (pl)
BR (1) BR0308394A (pl)
CA (1) CA2478948A1 (pl)
CR (1) CR7490A (pl)
DE (1) DE60311236T2 (pl)
DK (1) DK1482925T3 (pl)
ES (1) ES2280766T3 (pl)
HR (1) HRP20040923A2 (pl)
IL (1) IL164032A0 (pl)
MX (1) MXPA04008881A (pl)
NO (1) NO20044279L (pl)
NZ (1) NZ535427A (pl)
PE (1) PE20040157A1 (pl)
PL (1) PL372490A1 (pl)
PT (1) PT1482925E (pl)
RS (1) RS89504A (pl)
RU (1) RU2314299C2 (pl)
TW (1) TW200307674A (pl)
UA (1) UA78027C2 (pl)
UY (1) UY27715A1 (pl)
WO (1) WO2003075915A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
CN101326169B (zh) * 2005-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 作为抗炎剂的糖皮质激素受体调节剂
CA2632531A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Propionamide compounds as antiinflammatory agents
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101289408B (zh) * 2007-04-18 2013-02-27 中国科学院上海药物研究所 非甾体类孕激素受体调节剂及其制备方法、药物组合物和用途
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) * 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AU2018267059B2 (en) * 2017-05-10 2021-08-12 Ventana Medical Systems, Inc. Stabilized two-part hematoxylin solution utilizing pH adjustment
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
NO312255B1 (no) * 2000-06-28 2002-04-15 Pgs Reservoir Consultants As Verktöy for gjennomhulling av et langsgående veggparti av et fôringsrör
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
JP2004516841A (ja) * 2000-12-28 2004-06-10 シエーリング アクチエンゲゼルシャフト プロゲステロンレセプターアイソフォーム特異的リガンドおよび組織選択的プロゲステロンレセプターリガンドについてスクリーニングする方法

Also Published As

Publication number Publication date
US7388006B2 (en) 2008-06-17
DE60311236D1 (de) 2007-03-08
AR035904A1 (es) 2004-07-28
RS89504A (sr) 2006-10-27
CR7490A (es) 2006-02-07
PE20040157A1 (es) 2004-06-03
WO2003075915A1 (en) 2003-09-18
JP2005526064A (ja) 2005-09-02
CN1652768A (zh) 2005-08-10
PT1482925E (pt) 2007-04-30
TW200307674A (en) 2003-12-16
MXPA04008881A (es) 2004-12-07
DE60311236T2 (de) 2008-02-14
BR0308394A (pt) 2005-01-25
ES2280766T3 (es) 2007-09-16
RU2004130430A (ru) 2005-08-10
US20030232824A1 (en) 2003-12-18
RU2314299C2 (ru) 2008-01-10
AU2003209720A1 (en) 2003-09-22
CA2478948A1 (en) 2003-09-18
NZ535427A (en) 2006-08-31
HRP20040923A2 (en) 2004-12-31
EP1482925A1 (en) 2004-12-08
EP1482925B1 (en) 2007-01-17
UY27715A1 (es) 2003-08-29
NO20044279L (no) 2004-12-08
DK1482925T3 (da) 2007-05-14
IL164032A0 (en) 2005-12-18
UA78027C2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
PL372490A1 (pl) 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
HUP0204291A3 (en) Use of composition containing estrogen and drospirenone for hormone replacement therapy
AU2003294264A1 (en) Non-steroidal farnesoid x receptor modulators and methods for the use thereof
PL345887A1 (en) Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU6001001A (en) Cranial flap clamp and instrument for use therewith
ZA200701156B (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
NO20010468L (no) Anvendelse av biogene østrogensulfamater til hormonerstatningsterapi
Nekora-Azak RETRACTED: temporomandibular disorders in relation to female reproductive hormones: a literature review
AU2003259152A8 (en) Cell therapy for regeneration
SG109523A1 (en) Lithographic projection apparatus and reflector assembly for use in said apparatus
IL161746A0 (en) Closed automated system for tissue based therapy, dosing and administration using same
AU2003286639A8 (en) Mixing and delivery medical syringe system for therapeutic compositions
AU2002345500A1 (en) Sams modifiers of the p53 pathway and methods of use
AU2003273226A1 (en) System for diagnosing and treating sleep apnea
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
EP1902691B8 (de) Osteoporose-Orthese
SI1482925T1 (sl) 5-(2-hidroksi-3-(1-(trifluorometilfenil)-ciklopropil)-propionilamino)- ftalid in sorodne spojine z aktivnostjo moduliranja progesteronskega receptorja za uporabo pri kontroli plodnosti in hormonski nadomestni terapiji
ATE270554T1 (de) Kombination der progesteron und mifepristone für krebs-therapie
DK1525215T3 (da) Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
WO2004028453A3 (en) Methods for preventing and treating obesity in patients with mc4 receptor mutations
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
NO20076683L (no) Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse
SG162615A1 (en) Bazedoxifene treatment regimens
ATE536904T1 (de) Gerät zur unterstützung der atmung

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)